Clinically relevant models for cancer therapy development
We are committed to providing academic PIs the most innovative pre-clinical models and services to delineate the mechanisms underlying disease and enable you to select efficacious drugs, including a range of immunotherapeutics to treat targeted tumor types alone or in combination.
In collaboration with 25 national medical centers, we have banked over 400 Patient-Derived Xenograft (PDX) models, many with detailed clinical information, such as including treatment history and extensive characterization, established in the highly immunodeficient NSG™ mice.
Our PDX Live™ collection includes 16 different PDX models - all of which are maintained live in mice for quicker delivery. These PDX Live™ tumors are now available at a special price. Other cryopreserved models are also available – contact us for details.
Our PDX program for academic PIs provides tumor models at a lower passage, more accurately reflecting clinical samples compared to other PDX resources. Other advantages include:
- Early passage samples retain cancer heterogeneity.
- Models are grown directly from clinical samples, not cell lines.
- Clinician-directed program includes current patient demographics.
- Cancer models reflect a spectrum of relevant mutations.
To take advantage of special pricing for academic PIs, contact your regional representative.
PDX-engrafted mice are a fast and cost-effective platform to simulate trials, evaluate multiple drugs alone or in combination, and produce predictive data.
